ArticleFrontiers in endocrinology2025

Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes.

Alessandro Colletta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.